MedPath

OTO-313 in Subjects With Unilateral Subjective Tinnitus

Phase 2
Completed
Conditions
Subjective Tinnitus
Interventions
Drug: Placebo
Registration Number
NCT04829214
Lead Sponsor
Otonomy, Inc.
Brief Summary

The purpose of this study is to determine the efficacy of OTO-313 in subjects with unilateral tinnitus and to determine the safety and tolerability of OTO-313 in subjects with unilateral tinnitus.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
153
Inclusion Criteria
  • Subject has early-onset subjective unilateral tinnitus that is persistent (consistently aware of their tinnitus throughout much of the waking day).
  • Subject is able to use the diary to complete their daily tinnitus ratings.
  • Subject's tinnitus is likely of cochlear origin, e.g., associated with sensorineural hearing loss; acute hearing loss from noise trauma, barotrauma, or traumatic cochlear injury (acute acoustic trauma, blast trauma, middle ear surgery, inner ear barotrauma); age related hearing loss; resolved otitis media; ototoxic drug exposure.
  • Subject is willing to comply with the protocol and attend all study visits.
Exclusion Criteria
  • Subject has pulsatile tinnitus, temporomandibular joint disease (TMJ) associated with tinnitus perception, tinnitus resulting from traumatic head or neck injury, or tinnitus resulting from a tumor or stroke.
  • Subject is pregnant, lactating, or undergoing fertility treatment.
  • Subject has other clinically significant illness, medical condition or medical history at Screening or Baseline that, in the Investigator's opinion, would likely reduce the safety of study participation or compliance with study procedures.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
OTO-313OTO-313-
Primary Outcome Measures
NameTimeMethod
Percentage of Tinnitus Functional Index (TFI) Responders at Weeks 4 and at Week 8Week 4 and Week 8 (both had to meet criterion for the subject to be considered a "responder")

The TFI is a validated, 25-item questionnaire; index score from 0 to 100; higher scores indicate a greater problem with tinnitus. A responder is considered as any subject with at least a 13-point improvement from Baseline on the (TFI). This responder analysis required both Week 4 and Week 8 to have a 13-point improvement from Baseline.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in Daily Tinnitus Loudness at Week 8The average is calculated for the Baseline and for each study week. Reported here is the change from Baseline to Week 8.

Numerical rating scale (NRS) from 0 (No Tinnitus) to 10 (Extremely Loud Tinnitus) collected every day. Post-baseline weekly NRS scores will be calculated as the average score of all recorded diary entries within each study week.

Change From Baseline in Daily Tinnitus Annoyance at Week 8The average is calculated for the Baseline and for each study week. Reported here is the change from Baseline to Week 8

Numerical rating scale from 0 (Not Annoying) to 10 (Extremely Annoying) collected every day. Post-baseline weekly NRS scores will be calculated as the average score of all recorded diary entries within each study week.

Patient Global Impression of Change at Week 8Week 8 reported here

Change in overall tinnitus status as perceived by the subject as assessed at the Week 8 visit. Subjects were asked, "Since the beginning of the clinical study, how would you rate your tinnitus?" and had the choice to answer from very much worse (-3) to very much improved (3). The mean change from baseline at Week 8 is reported here.

Trial Locations

Locations (46)

ChicagoENT

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Centrum Medyczne ZDROWA

๐Ÿ‡ต๐Ÿ‡ฑ

Krakรณw, Poland

Dartmouth-Hitchcock Medical Center/Mary Hitchcock Memorial Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Lebanon, New Hampshire, United States

NHS Tayside

๐Ÿ‡ฌ๐Ÿ‡ง

Dundee, United Kingdom

Carolina Ear, Nose & Throat Clinic/CENTRI Inc.

๐Ÿ‡บ๐Ÿ‡ธ

Orangeburg, South Carolina, United States

Central California Clinical Research

๐Ÿ‡บ๐Ÿ‡ธ

Fresno, California, United States

Breathe Clear Institute

๐Ÿ‡บ๐Ÿ‡ธ

Torrance, California, United States

Tandem Clinical Research

๐Ÿ‡บ๐Ÿ‡ธ

Marrero, Louisiana, United States

Ear Research Foundation

๐Ÿ‡บ๐Ÿ‡ธ

Sarasota, Florida, United States

Center for Specialized Medicine, Department of Otolaryngology-Head and Neck Surgery

๐Ÿ‡บ๐Ÿ‡ธ

Saint Louis, Missouri, United States

UC Health Otolaryngology-Head and Neck Surgery

๐Ÿ‡บ๐Ÿ‡ธ

Cincinnati, Ohio, United States

Charlotte Eye Ear Nose & Throat Associates, P.A.

๐Ÿ‡บ๐Ÿ‡ธ

Matthews, North Carolina, United States

Spartanburg/Greer ENT & Allergy

๐Ÿ‡บ๐Ÿ‡ธ

Spartanburg, South Carolina, United States

Alamo ENT Associates

๐Ÿ‡บ๐Ÿ‡ธ

San Antonio, Texas, United States

Chrysalis Clinical Research

๐Ÿ‡บ๐Ÿ‡ธ

Saint George, Utah, United States

Vanderbilt University Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Nashville, Tennessee, United States

HNO Praxis - Marianne Grohe

๐Ÿ‡ฉ๐Ÿ‡ช

Kรถln, Germany

Centrum Medyczne Kwiatowa

๐Ÿ‡ต๐Ÿ‡ฑ

Bydgoszcz, Poland

HNO Praxis am Necker

๐Ÿ‡ฉ๐Ÿ‡ช

Heidelberg, Germany

HNO-Gemeinschaftspraxis

๐Ÿ‡ฉ๐Ÿ‡ช

Heidelberg, Germany

Universitรคtsklinikum Mannheim Klinik fรผr Otorhinolaryngologie, Kopf- und Halschirurgie

๐Ÿ‡ฉ๐Ÿ‡ช

Mannheim, Germany

Klinikum der Universitaet Muenchen

๐Ÿ‡ฉ๐Ÿ‡ช

Muenchen, Germany

Centrum Medyczne PROMED

๐Ÿ‡ต๐Ÿ‡ฑ

Krakรณw, Poland

University Hospitals of Leicester NHS Trust

๐Ÿ‡ฌ๐Ÿ‡ง

Leicester, United Kingdom

University Hospitals Birmingham NHS Foundation Trust

๐Ÿ‡ฌ๐Ÿ‡ง

Birmingham, United Kingdom

Norfolk and Norwich University Hospitals NHS Trust

๐Ÿ‡ฌ๐Ÿ‡ง

Norwich, United Kingdom

Universitรคtsklinikum Carl Gustav Carus Dresden

๐Ÿ‡ฉ๐Ÿ‡ช

Dresden, Germany

HNO - Praxis Gรถttingen

๐Ÿ‡ฉ๐Ÿ‡ช

Gรถttingen, Germany

Rush University Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital

๐Ÿ‡ฉ๐Ÿ‡ช

Jena, Germany

Colorado ENT & Allergy

๐Ÿ‡บ๐Ÿ‡ธ

Colorado Springs, Colorado, United States

ENT and Allergy Associates of FL

๐Ÿ‡บ๐Ÿ‡ธ

Boynton Beach, Florida, United States

ENT and Allergy Associates of Florida, LLC

๐Ÿ‡บ๐Ÿ‡ธ

Port Saint Lucie, Florida, United States

Dent Neurosciences Research Center

๐Ÿ‡บ๐Ÿ‡ธ

Amherst, New York, United States

Research Centers of America

๐Ÿ‡บ๐Ÿ‡ธ

Hollywood, Florida, United States

Fort Worth ENT

๐Ÿ‡บ๐Ÿ‡ธ

Fort Worth, Texas, United States

ENT Associates of Texas

๐Ÿ‡บ๐Ÿ‡ธ

McKinney, Texas, United States

Eastern Virginia Medical School Department of Otolatyngology

๐Ÿ‡บ๐Ÿ‡ธ

Norfolk, Virginia, United States

Advanced Otolaryngology, P.C. DBA Richmond ENT

๐Ÿ‡บ๐Ÿ‡ธ

Richmond, Virginia, United States

MT Medic Specjalistyczna Pralctyka Lekarska Tomasz Stapiล„ski

๐Ÿ‡ต๐Ÿ‡ฑ

Krosno, Poland

Sheffield Teaching Hospitals NHS Foundation Trust

๐Ÿ‡ฌ๐Ÿ‡ง

Sheffield, United Kingdom

Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina

๐Ÿ‡บ๐Ÿ‡ธ

Charleston, South Carolina, United States

Piedmont Ear, Nose & Throat Associates, PA

๐Ÿ‡บ๐Ÿ‡ธ

Winston-Salem, North Carolina, United States

University of Colorado, Department of Otolaryngology

๐Ÿ‡บ๐Ÿ‡ธ

Aurora, Colorado, United States

Kentuckian Ear, Nose & Throat

๐Ÿ‡บ๐Ÿ‡ธ

Louisville, Kentucky, United States

Advanced ENT and Allergy, PLLC

๐Ÿ‡บ๐Ÿ‡ธ

Louisville, Kentucky, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath